Request sourcing
What is Ustekinumab?
Ustekinumab, the active ingredient in Otulfi, is a monoclonal antibody presented as a subcutaneous injection for subcutaneous use. It treats moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease in adults. GNH USA supplies Otulfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
GNH USA supplies Otulfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Ustekinumab used for?
Otulfi is a biologic therapy that targets key inflammatory pathways involved in several chronic immune‑mediated diseases.
- Plaque psoriasis: reduces skin lesions and improves quality of life. - Psoriatic arthritis: alleviates joint inflammation and slows structural damage. - Crohn's disease: induces remission and maintains symptom control in moderate to severe cases.
What are the side effects of Ustekinumab?
Adverse reactions to ustekinumab vary in frequency and severity.
Common Side Effects: - Upper respiratory tract infection. - Headache. - Fatigue. - Injection site erythema. - Diarrhea. - Nausea.
Serious or Rare Side Effects: - Serious infections (e.g., tuberculosis, fungal infections). - Malignancies such as lymphoma. - Hypersensitivity reactions including anaphylaxis. - New onset or worsening inflammatory bowel disease. - Cardiovascular events. - Neurologic disorders such as demyelinating disease.
What precautions apply to Ustekinumab?
When prescribing ustekinumab, clinicians should consider several safety aspects.
- Infection risk: screen for latent TB and monitor for signs of infection. - Vaccination: avoid live vaccines during treatment. - Cancer surveillance: monitor patients with a history of malignancy. - Pregnancy and lactation: use only if the potential benefit justifies the risk. - Storage at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.
What does Ustekinumab interact with?
Ustekinumab may interact with other agents that affect immune function.
Major Interactions (Avoid): - Live vaccines: concurrent use can cause severe infection. - Systemic immunosuppressants (e.g., high‑dose corticosteroids): may increase infection risk.
Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., azoles): may require monitoring for opportunistic infections. - Antiviral drugs: - Anticoagulants antico . - Vaccines . - Cytok . - .
